Precision Cardiology Market Size & Growth Analysis

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Precision Cardiology Market Size Analysis

Global Precision Cardiology Market Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value

North America Market Analysis

Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value
U.S.
1. By Offering
  1. Introduction
    1. Offering By Value
  2. Service
    1. By Value
  3. Product
    1. By Value
2. By Sample
  1. Introduction
    1. Sample By Value
  2. Blood
    1. By Value
  3. Non-Blood
    1. By Value
  4. Saliva
    1. By Value
  5. Buccal swabs
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Sequencing
    1. By Value
    2. Next-generation sequencing (NGS)
      1. Next-generation sequencing (NGS) By Value
    3. Sanger sequencing
      1. Sanger sequencing By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Microarray
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Cardiomyopathy
    1. By Value
  3. Arrhythmia
    1. By Value
  4. Aortopathy and Vascular Diseases
    1. By Value
  5. Familial Hypercholesterolemia (FH)
    1. By Value
  6. Congenital Heart Defects and Syndromes
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Academic and Research Institute
    1. By Value
Canada

Europe Market Analysis

Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value
U.K.
1. By Offering
  1. Introduction
    1. Offering By Value
  2. Service
    1. By Value
  3. Product
    1. By Value
2. By Sample
  1. Introduction
    1. Sample By Value
  2. Blood
    1. By Value
  3. Non-Blood
    1. By Value
  4. Saliva
    1. By Value
  5. Buccal swabs
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Sequencing
    1. By Value
    2. Next-generation sequencing (NGS)
      1. Next-generation sequencing (NGS) By Value
    3. Sanger sequencing
      1. Sanger sequencing By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Microarray
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Cardiomyopathy
    1. By Value
  3. Arrhythmia
    1. By Value
  4. Aortopathy and Vascular Diseases
    1. By Value
  5. Familial Hypercholesterolemia (FH)
    1. By Value
  6. Congenital Heart Defects and Syndromes
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Academic and Research Institute
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value
China
1. By Offering
  1. Introduction
    1. Offering By Value
  2. Service
    1. By Value
  3. Product
    1. By Value
2. By Sample
  1. Introduction
    1. Sample By Value
  2. Blood
    1. By Value
  3. Non-Blood
    1. By Value
  4. Saliva
    1. By Value
  5. Buccal swabs
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Sequencing
    1. By Value
    2. Next-generation sequencing (NGS)
      1. Next-generation sequencing (NGS) By Value
    3. Sanger sequencing
      1. Sanger sequencing By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Microarray
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Cardiomyopathy
    1. By Value
  3. Arrhythmia
    1. By Value
  4. Aortopathy and Vascular Diseases
    1. By Value
  5. Familial Hypercholesterolemia (FH)
    1. By Value
  6. Congenital Heart Defects and Syndromes
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Academic and Research Institute
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value
UAE
1. By Offering
  1. Introduction
    1. Offering By Value
  2. Service
    1. By Value
  3. Product
    1. By Value
2. By Sample
  1. Introduction
    1. Sample By Value
  2. Blood
    1. By Value
  3. Non-Blood
    1. By Value
  4. Saliva
    1. By Value
  5. Buccal swabs
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Sequencing
    1. By Value
    2. Next-generation sequencing (NGS)
      1. Next-generation sequencing (NGS) By Value
    3. Sanger sequencing
      1. Sanger sequencing By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Microarray
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Cardiomyopathy
    1. By Value
  3. Arrhythmia
    1. By Value
  4. Aortopathy and Vascular Diseases
    1. By Value
  5. Familial Hypercholesterolemia (FH)
    1. By Value
  6. Congenital Heart Defects and Syndromes
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Academic and Research Institute
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Offering
1. Introduction
  1. Offering By Value
2. Service
  1. By Value
3. Product
  1. By Value
By Sample
1. Introduction
  1. Sample By Value
2. Blood
  1. By Value
3. Non-Blood
  1. By Value
4. Saliva
  1. By Value
5. Buccal swabs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Sequencing
  1. By Value
  2. Next-generation sequencing (NGS)
    1. Next-generation sequencing (NGS) By Value
  3. Sanger sequencing
    1. Sanger sequencing By Value
3. Polymerase Chain Reaction (PCR)
  1. By Value
4. Microarray
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cardiomyopathy
  1. By Value
3. Arrhythmia
  1. By Value
4. Aortopathy and Vascular Diseases
  1. By Value
5. Familial Hypercholesterolemia (FH)
  1. By Value
6. Congenital Heart Defects and Syndromes
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Diagnostic Laboratories
  1. By Value
4. Academic and Research Institute
  1. By Value
Brazil
1. By Offering
  1. Introduction
    1. Offering By Value
  2. Service
    1. By Value
  3. Product
    1. By Value
2. By Sample
  1. Introduction
    1. Sample By Value
  2. Blood
    1. By Value
  3. Non-Blood
    1. By Value
  4. Saliva
    1. By Value
  5. Buccal swabs
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Sequencing
    1. By Value
    2. Next-generation sequencing (NGS)
      1. Next-generation sequencing (NGS) By Value
    3. Sanger sequencing
      1. Sanger sequencing By Value
  3. Polymerase Chain Reaction (PCR)
    1. By Value
  4. Microarray
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Cardiomyopathy
    1. By Value
  3. Arrhythmia
    1. By Value
  4. Aortopathy and Vascular Diseases
    1. By Value
  5. Familial Hypercholesterolemia (FH)
    1. By Value
  6. Congenital Heart Defects and Syndromes
    1. By Value
5. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Diagnostic Laboratories
    1. By Value
  4. Academic and Research Institute
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Precision Cardiology Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

ARUP Laboratories
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Quest Diagnostics
CENTOGENE N.V.
Eurofins Scientific
GENinCode
Exact Sciences Corporation
Fulgent Genetics Inc.
Illumina Inc.
DNA Genotek Inc.
Thermo Fisher Scientific Inc.
Abbott Laboratories
BioMerieux SA10.13 Becton, Dickinson And Company
Danaher Corporation
QIAGEN N.V

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment